Pfizer Reports Fourth Quarter and Full-Year 2023 Results; Enters 2024 With a Solid Foundation

Pfizer reported its results for the fourth quarter and full year of 2023. Read more

We Invest in Changing Lives

Welcome to our shareholder community. Here you will find updates on our innovation pipeline progress, performance results, and corporate milestones. You’ll also have the opportunity to hear from our management team. Sign up now for Pfizer Investor Insights to receive information about the company and your investment.

Pfizer Invests $43 Billion to Battle Cancer

Pfizer continues to invest significant capital in the next generation of potential cancer breakthroughs, having announced its proposed acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Read more

Investors, Submit Your Question to Pfizer

We want to hear from you to help ensure that we are providing content that is informative and relevant.

Submit a question here about Pfizer’s R&D pipeline, Pfizer’s capital allocation objectives, or Pfizer’s roadmap for the future.

In the coming weeks and months, we’ll compile answers to common questions, giving you a way to hear from management on topics of interest to you.

Pfizer continues to advance groundbreaking work across all our therapeutics areas while delivering strong results in our innovative R&D pipeline and returning value to shareholders through dividends.

Albert Bourla

Chairman and CEO